Treatment Options for Invasive Fungal Infections

Clinicians face an increasing occurrence of invasive fungal infections. These are due not only to traditional yeast and mould species but also to rare pathogens that can be difficult to treat. The introduction of new agents has expanded the options for treating common and rare mycotic infections wit...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2006-06, Vol.26 (6P2), p.55S-60S
Main Author: Ashley, Elizabeth S. Dodds
Format: Article
Language:English
Subjects:
amphotericin B
Amphotericin B - administration & dosage
Amphotericin B - adverse effects
Amphotericin B - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antifungal agents
Antifungal Agents - administration & dosage
Antifungal Agents - adverse effects
Antifungal Agents - therapeutic use
antifungal therapy
azoles
Azoles - administration & dosage
Azoles - adverse effects
Azoles - therapeutic use
Biological and medical sciences
Drug Interactions
Echinocandins
Fungal Proteins - administration & dosage
Fungal Proteins - adverse effects
Fungal Proteins - therapeutic use
Fungemia - drug therapy
Humans
Medical sciences
Peptides, Cyclic - administration & dosage
Peptides, Cyclic - adverse effects
Peptides, Cyclic - therapeutic use
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinicians face an increasing occurrence of invasive fungal infections. These are due not only to traditional yeast and mould species but also to rare pathogens that can be difficult to treat. The introduction of new agents has expanded the options for treating common and rare mycotic infections with antifungal efficacy at least equal, and safety far superior, to that of a once‐limited choice of therapies. Patients with invasive mycoses frequently have concomitant disorders and require multidrug regimens. Clinicians must be aware of the potential for interactions among agents available for treating invasive mycoses in patients with serious underlying conditions.
ISSN:0277-0008
1875-9114
DOI:10.1592/phco.26.6part2.55S